[Multicentric study on a topical compound with lymph-draining action in the treatment of the phlebostatic ulcer of the inferior limbs].
Phlebostatic sore of the lower limbs is a typical chronic venous insufficiency complication and is still a widely controversial issue in its treatment. The common therapies, in fact, are not yet standardized and they not show complete efficacy. Since 2005 to 2007 a multicentric clinical trial was conducted at the Plastic and Reconstructive Surgery of "Sapienza" University of Rome and at the Plastic and Reconstructive Surgery Department, University of Perugia, in order to evaluate the efficacy of the Idrastin lymph-draining cream in patients with phlebostatic sores of the lower limbs. This study enrolled on 80 patients, split into 2 homogeneous groups of 40 patients: group A was treated by only elastocompressive therapy, group B by elastocompressive therapy and Idrastin. Multicentric analysis has considered the following parameters: local pain, perilesional flogosis , granulation tissue, perilesional tissue tropism healing time. In the group B results highlighted: reduction of the local pain, stopped in 72 hours; flogosis decrease disappeared in one week; tissue granulation growth in one week; lesion healing in 4 weeks. These results pointed out statistically significance of the variables considered. In our opinion Idrastin compounds such as phytoessence of hops and Hedera helix, had contributed to analgesia; Aesculus hippocastanum, and Vitis vinifera and Ruscus aculeatus phytoessence showed anti-flogistic action; allantoin and Centella asiatica and jaluronic acid aided to sore healing. Idrastin gives an effective support to the treatment of the phlebostatic sores warrants a faster and more effective healing process, than to the wounds treated by only the elastocompressive therapy.
Chiummariello
S
S
Università degli Studi di Perugia, Cattedra di Chirurgia Plastica e Ricostruttiva.
De Gado
F
F
Monarca
C
C
Ruggiero
M
M
Carlesimo
B
B
Scuderi
N
N
Alfano
C
C
D000279:Administration, Cutaneous; D001284:Atrophy; D003131:Combined Modality Therapy; D003646:Debridement; D003879:Dermatologic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D048909:Diabetes Complications / Q000188:drug therapy / Q000601:surgery / Q000628:therapy; D004487:Edema / Q000150:complications / Q000188:drug therapy / Q000628:therapy; D005260:Female; D006801:Humans; D008196:Lymph / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D009824:Ointments; D008517:Phytotherapy; D028321:Plant Preparations / Q000008:administration & dosage / Q000627:therapeutic use*; D011711:Pyoderma / Q000150:complications; D012008:Recurrence; D012501:Saphenous Vein / Q000601:surgery; D053828:Stockings, Compression; D014647:Varicose Ulcer / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery / Q000628:therapy; D014945:Wound Healing
D003879:Dermatologic Agents; C549516:Idrastin; D009824:Ointments; D028321:Plant Preparations